Related Experiment Video
Updated: Mar 1, 2026

Through-the-Wall Blood Sampling Method to Minimize Sleep Disruption in Clinical Settings
Published on: June 13, 2025
Citrate versus heparin anticoagulation in continuous renal replacement therapy in small children
Paulien A M A Raymakers-Janssen1, Marc Lilien2, Ingrid A van Kessel3
1Department of Pediatric Intensive Care, Wilhelmina Children's Hospital, University Medical Center Utrecht, Lundlaan 6, 3584 EA, Utrecht, The Netherlands. p.a.m.a.raymakers-janssen@umcutrecht.nl.
Insights
Citrate anticoagulation in pediatric continuous renal replacement therapy (CRRT) significantly extends circuit survival time compared to heparin. This study demonstrates citrate
Area of Science:
- Pediatric Nephrology
- Critical Care Medicine
- Biomedical Engineering
Background:
- Heparin is the standard anticoagulant for adult continuous renal replacement therapy (CRRT).
- Limited data exists on citrate's safety and efficacy in pediatric CRRT, especially in infants and toddlers.
- Adverse effects of citrate in this population are not well-documented.
Purpose of the Study:
- To prospectively evaluate the use of citrate as an anticoagulant in critically ill small children undergoing CRRT.
- To compare circuit survival time between citrate and heparin anticoagulation in pediatric CRRT.
- To assess the safety of citrate, including toxicity and electrolyte balance, in this patient group.
Main Methods:
- A prospective study involving critically ill children who underwent CRRT with small filters.
- Patients received either heparin or citrate anticoagulation per a strict protocol.
- Primary outcome was circuit survival time; secondary outcomes included alkalosis, citrate toxicity, and red blood cell transfusions.
Main Results:
- Citrate use resulted in significantly longer median circuit survival time (45.2 hours) compared to heparin (21 hours) (p < 0.001).
- No citrate toxicity was observed in patients receiving citrate anticoagulation.
- No significant differences in electrolyte balance or red blood cell transfusions were noted between the two groups.
Conclusions:
- Regional citrate anticoagulation significantly prolongs circuit survival time in pediatric CRRT, enhancing treatment efficiency.
- Citrate is a safe and effective anticoagulant for CRRT in critically ill small children.
- These findings support the wider adoption of citrate in pediatric CRRT.
Background:
Citrate is preferred over heparin as an anticoagulant in adult continuous renal replacement therapy (CRRT). However, its potential adverse effects and data on use in CRRT in infants and toddlers is limited. We conducted a prospective study on using citrate in CRRT in critically ill small children.
Methods:
Children who underwent CRRT with the smallest filter in our PICU between November 2011 and November 2016 were included. Both heparin and citrate were applied according to a strict protocol. Our primary outcome was circuit survival time. Secondary outcomes were alkalosis, citrate toxicity, and number of red blood cell transfusions.
Results:
Heparin was used in six patients (121 circuits, total CRRT time 3723 h). Citrate was used in 14 patients (105 circuits, total CRRT time 4530 h). Median circuit survival time with heparin was 21 h (IQR 14.5-27.5) compared to 45.2 h (IQR 37.5-52.8) with citrate (p < 0.001). Actual administered effluent dose compared to prescribed dose was 85% (IQR 69-98%) with heparin compared to 92% (IQR 88-98%) with citrate (p = 0.31). No patient treated with citrate developed citrate toxicity. No other differences in electrolytes were found between the two CRRT regimes. In the heparin group, a median of 6.5 units of red blood cells (IQR 1.5-23.8) were given during CRRT, compared to three in the citrate group (IQR 2.0-5.0, p = 0.12).
Conclusions:
Use of regional citrate significantly prolongs circuit survival time and thereby should increase CRRT efficiency when compared to heparin. In addition, citrate appears safe for CRRT in critically ill small children.
Related Concept Videos
Continuous Renal Replacement Therapy
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Acute Kidney Injury V: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Pharmacokinetics in Pediatric Patients: Drug Excretion
Cardiac Catheterization I: Pre-Procedure Overview

